TNFL4_HUMAN
ID TNFL4_HUMAN Reviewed; 183 AA.
AC P23510; Q5JZA5; Q8IV74; Q9HCN9;
DT 01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1991, sequence version 1.
DT 03-AUG-2022, entry version 176.
DE RecName: Full=Tumor necrosis factor ligand superfamily member 4;
DE AltName: Full=Glycoprotein Gp34;
DE AltName: Full=OX40 ligand;
DE Short=OX40L;
DE AltName: Full=TAX transcriptionally-activated glycoprotein 1;
DE AltName: CD_antigen=CD252;
GN Name=TNFSF4; Synonyms=TXGP1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=1996093; DOI=10.1128/mcb.11.3.1313-1325.1991;
RA Miura S., Ohtani K., Numata N., Niki M., Ohbo K., Ina Y., Gojobori T.,
RA Tanaka Y., Tozawa H., Nakamura M., Sugamura K.;
RT "Molecular cloning and characterization of a novel glycoprotein, gp34, that
RT is specifically induced by the human T-cell leukemia virus type I
RT transactivator p40tax.";
RL Mol. Cell. Biol. 11:1313-1325(1991).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=7913952; DOI=10.1084/jem.180.2.757;
RA Godfrey W.R., Fagnoni F.F., Harara M.A., Buck D., Engleman E.G.;
RT "Identification of a human OX-40 ligand, a costimulator of CD4+ T cells
RT with homology to tumor necrosis factor.";
RL J. Exp. Med. 180:757-762(1994).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16710414; DOI=10.1038/nature04727;
RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT "The DNA sequence and biological annotation of human chromosome 1.";
RL Nature 441:315-321(2006).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC TISSUE=Testis;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [7]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67.
RX PubMed=11197696; DOI=10.1038/sj.gene.6363709;
RA Hikami K., Tsuchiya N., Tokunaga K.;
RT "New variations in human OX40 ligand (CD134L) gene.";
RL Genes Immun. 1:521-522(2000).
RN [8]
RP CHARACTERIZATION.
RX PubMed=8076595; DOI=10.1002/j.1460-2075.1994.tb06715.x;
RA Baum P.R., Gayle R.B. III, Ramsdell F., Srinivasan S., Sorensen R.A.,
RA Watson M.L., Seldin M.F., Baker E., Sutherland G.R., Clifford K.N.,
RA Alderson M.R., Goodwin R.G., Fanslow W.C.;
RT "Molecular characterization of murine and human OX40/OX40 ligand systems:
RT identification of a human OX40 ligand as the HTLV-1-regulated protein
RT gp34.";
RL EMBO J. 13:3992-4001(1994).
RN [9]
RP INVOLVEMENT IN SUSCEPTIBILITY TO SLE.
RX PubMed=18059267; DOI=10.1038/ng.2007.47;
RA Cunninghame Graham D.S., Graham R.R., Manku H., Wong A.K., Whittaker J.C.,
RA Gaffney P.M., Moser K.L., Rioux J.D., Altshuler D., Behrens T.W.,
RA Vyse T.J.;
RT "Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to
RT systemic lupus erythematosus.";
RL Nat. Genet. 40:83-89(2008).
RN [10]
RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 48-183 IN COMPLEX WITH TNFRSF4,
RP SUBUNIT, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-152.
RX PubMed=16905106; DOI=10.1016/j.str.2006.06.015;
RA Compaan D.M., Hymowitz S.G.;
RT "The crystal structure of the costimulatory OX40-OX40L complex.";
RL Structure 14:1321-1330(2006).
CC -!- FUNCTION: Cytokine that binds to TNFRSF4. Co-stimulates T-cell
CC proliferation and cytokine production.
CC -!- SUBUNIT: Homotrimer. {ECO:0000269|PubMed:16905106}.
CC -!- INTERACTION:
CC P23510; P43489: TNFRSF4; NbExp=2; IntAct=EBI-11724451, EBI-15596193;
CC P23510; P43488: Tnfsf4; Xeno; NbExp=2; IntAct=EBI-11724451, EBI-519690;
CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane protein.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=P23510-1; Sequence=Displayed;
CC Name=2;
CC IsoId=P23510-2; Sequence=VSP_056288;
CC -!- INDUCTION: By HTLV-1 transactivator p40-Tax.
CC -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic,
CC relapsing, inflammatory, and often febrile multisystemic disorder of
CC connective tissue, characterized principally by involvement of the
CC skin, joints, kidneys and serosal membranes. It is of unknown etiology,
CC but is thought to represent a failure of the regulatory mechanisms of
CC the autoimmune system. The disease is marked by a wide range of system
CC dysfunctions, an elevated erythrocyte sedimentation rate, and the
CC formation of LE cells in the blood or bone marrow.
CC {ECO:0000269|PubMed:18059267}. Note=Disease susceptibility is
CC associated with variants affecting the gene represented in this entry.
CC The upstream region of TNFSF4 contains a single risk haplotype for SLE,
CC which is correlated with increased expression of both cell-surface
CC TNFSF4 and TNFSF4 transcripts. Increased levels of TNFSF4 are thought
CC to augment T-cell-APC interaction and the functional consequences of T-
CC cell activation, thereby destabilizing peripheral tolerance.
CC -!- SIMILARITY: Belongs to the tumor necrosis factor family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; D90224; BAA14259.1; -; mRNA.
DR EMBL; X79929; CAA56284.1; -; mRNA.
DR EMBL; AK297932; BAG60249.1; -; mRNA.
DR EMBL; AL022310; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; CH471067; EAW90938.1; -; Genomic_DNA.
DR EMBL; BC041663; AAH41663.1; -; mRNA.
DR EMBL; AB042988; BAB18304.1; -; Genomic_DNA.
DR CCDS; CCDS1306.1; -. [P23510-1]
DR CCDS; CCDS72985.1; -. [P23510-2]
DR PIR; A39680; A39680.
DR RefSeq; NP_001284491.1; NM_001297562.1. [P23510-2]
DR RefSeq; NP_003317.1; NM_003326.4. [P23510-1]
DR PDB; 2HEV; X-ray; 2.41 A; F=51-183.
DR PDBsum; 2HEV; -.
DR AlphaFoldDB; P23510; -.
DR SMR; P23510; -.
DR DIP; DIP-3023N; -.
DR IntAct; P23510; 3.
DR MINT; P23510; -.
DR STRING; 9606.ENSP00000281834; -.
DR ChEMBL; CHEMBL3712900; -.
DR GlyGen; P23510; 4 sites.
DR iPTMnet; P23510; -.
DR PhosphoSitePlus; P23510; -.
DR BioMuta; TNFSF4; -.
DR DMDM; 121540; -.
DR jPOST; P23510; -.
DR MassIVE; P23510; -.
DR PaxDb; P23510; -.
DR PeptideAtlas; P23510; -.
DR PRIDE; P23510; -.
DR ProteomicsDB; 54122; -. [P23510-1]
DR ProteomicsDB; 70669; -.
DR ABCD; P23510; 51 sequenced antibodies.
DR Antibodypedia; 34389; 679 antibodies from 39 providers.
DR DNASU; 7292; -.
DR Ensembl; ENST00000281834.4; ENSP00000281834.3; ENSG00000117586.11. [P23510-1]
DR Ensembl; ENST00000367718.5; ENSP00000356691.1; ENSG00000117586.11. [P23510-2]
DR GeneID; 7292; -.
DR KEGG; hsa:7292; -.
DR MANE-Select; ENST00000281834.4; ENSP00000281834.3; NM_003326.5; NP_003317.1.
DR UCSC; uc001giv.4; human. [P23510-1]
DR CTD; 7292; -.
DR DisGeNET; 7292; -.
DR GeneCards; TNFSF4; -.
DR HGNC; HGNC:11934; TNFSF4.
DR HPA; ENSG00000117586; Low tissue specificity.
DR MalaCards; TNFSF4; -.
DR MIM; 152700; phenotype.
DR MIM; 603594; gene.
DR neXtProt; NX_P23510; -.
DR OpenTargets; ENSG00000117586; -.
DR Orphanet; 2073; Narcolepsy type 1.
DR Orphanet; 536; Systemic lupus erythematosus.
DR PharmGKB; PA36625; -.
DR VEuPathDB; HostDB:ENSG00000117586; -.
DR eggNOG; ENOG502ST4X; Eukaryota.
DR GeneTree; ENSGT00390000015127; -.
DR HOGENOM; CLU_091735_0_0_1; -.
DR InParanoid; P23510; -.
DR OMA; NTSCEDF; -.
DR OrthoDB; 1590205at2759; -.
DR PhylomeDB; P23510; -.
DR TreeFam; TF336384; -.
DR PathwayCommons; P23510; -.
DR Reactome; R-HSA-5669034; TNFs bind their physiological receptors.
DR SignaLink; P23510; -.
DR SIGNOR; P23510; -.
DR BioGRID-ORCS; 7292; 9 hits in 1070 CRISPR screens.
DR ChiTaRS; TNFSF4; human.
DR EvolutionaryTrace; P23510; -.
DR GenomeRNAi; 7292; -.
DR Pharos; P23510; Tbio.
DR PRO; PR:P23510; -.
DR Proteomes; UP000005640; Chromosome 1.
DR RNAct; P23510; protein.
DR Bgee; ENSG00000117586; Expressed in monocyte and 115 other tissues.
DR ExpressionAtlas; P23510; baseline and differential.
DR Genevisible; P23510; HS.
DR GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR GO; GO:0005125; F:cytokine activity; IEA:UniProtKB-KW.
DR GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
DR GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA:InterPro.
DR GO; GO:0032813; F:tumor necrosis factor receptor superfamily binding; ISS:BHF-UCL.
DR GO; GO:0002526; P:acute inflammatory response; ISS:BHF-UCL.
DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:BHF-UCL.
DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IDA:BHF-UCL.
DR GO; GO:0002215; P:defense response to nematode; ISS:BHF-UCL.
DR GO; GO:0006955; P:immune response; IEA:InterPro.
DR GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR GO; GO:0035709; P:memory T cell activation; ISS:BHF-UCL.
DR GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; ISS:BHF-UCL.
DR GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:BHF-UCL.
DR GO; GO:0032700; P:negative regulation of interleukin-17 production; IDA:BHF-UCL.
DR GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; ISS:BHF-UCL.
DR GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; ISS:BHF-UCL.
DR GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; ISS:BHF-UCL.
DR GO; GO:0050871; P:positive regulation of B cell activation; ISS:BHF-UCL.
DR GO; GO:1900281; P:positive regulation of CD4-positive, alpha-beta T cell costimulation; ISS:BHF-UCL.
DR GO; GO:0043372; P:positive regulation of CD4-positive, alpha-beta T cell differentiation; ISS:BHF-UCL.
DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:BHF-UCL.
DR GO; GO:0001819; P:positive regulation of cytokine production; IBA:GO_Central.
DR GO; GO:0002891; P:positive regulation of immunoglobulin mediated immune response; ISS:BHF-UCL.
DR GO; GO:0002639; P:positive regulation of immunoglobulin production; ISS:BHF-UCL.
DR GO; GO:0050729; P:positive regulation of inflammatory response; IDA:BHF-UCL.
DR GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:BHF-UCL.
DR GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:BHF-UCL.
DR GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR GO; GO:0032736; P:positive regulation of interleukin-13 production; ISS:BHF-UCL.
DR GO; GO:0032753; P:positive regulation of interleukin-4 production; IDA:BHF-UCL.
DR GO; GO:2000572; P:positive regulation of interleukin-4-dependent isotype switching to IgE isotypes; ISS:BHF-UCL.
DR GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR GO; GO:0043382; P:positive regulation of memory T cell differentiation; ISS:BHF-UCL.
DR GO; GO:0002726; P:positive regulation of T cell cytokine production; ISS:BHF-UCL.
DR GO; GO:0042102; P:positive regulation of T cell proliferation; IBA:GO_Central.
DR GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:BHF-UCL.
DR GO; GO:0002830; P:positive regulation of type 2 immune response; ISS:BHF-UCL.
DR GO; GO:0002819; P:regulation of adaptive immune response; ISS:BHF-UCL.
DR GO; GO:0050727; P:regulation of inflammatory response; ISS:BHF-UCL.
DR GO; GO:0035713; P:response to nitrogen dioxide; ISS:BHF-UCL.
DR GO; GO:0009615; P:response to virus; ISS:BHF-UCL.
DR GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR GO; GO:0035712; P:T-helper 2 cell activation; ISS:BHF-UCL.
DR CDD; cd00184; TNF; 1.
DR Gene3D; 2.60.120.40; -; 1.
DR InterPro; IPR021184; TNF_CS.
DR InterPro; IPR006052; TNF_dom.
DR InterPro; IPR042338; TNFSF4.
DR InterPro; IPR008983; Tumour_necrosis_fac-like_dom.
DR PANTHER; PTHR17534; PTHR17534; 1.
DR SMART; SM00207; TNF; 1.
DR SUPFAM; SSF49842; SSF49842; 1.
DR PROSITE; PS00251; TNF_1; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Cytokine; Disulfide bond; Glycoprotein;
KW Membrane; Reference proteome; Signal-anchor; Systemic lupus erythematosus;
KW Transmembrane; Transmembrane helix.
FT CHAIN 1..183
FT /note="Tumor necrosis factor ligand superfamily member 4"
FT /id="PRO_0000185493"
FT TOPO_DOM 1..23
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT TRANSMEM 24..50
FT /note="Helical; Signal-anchor for type II membrane protein"
FT /evidence="ECO:0000255"
FT TOPO_DOM 51..183
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT CARBOHYD 90
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 114
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 152
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:16905106"
FT CARBOHYD 157
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 97..181
FT /evidence="ECO:0000269|PubMed:16905106"
FT VAR_SEQ 1..51
FT /note="MERVQPLEENVGNAARPRFERNKLLLVASVIQGLGLLLCFTYICLHFSALQ
FT -> M (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:14702039,
FT ECO:0000303|PubMed:15489334"
FT /id="VSP_056288"
FT STRAND 61..70
FT /evidence="ECO:0007829|PDB:2HEV"
FT TURN 71..73
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 74..78
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 92..94
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 99..120
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 126..143
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 148..155
FT /evidence="ECO:0007829|PDB:2HEV"
FT STRAND 165..174
FT /evidence="ECO:0007829|PDB:2HEV"
SQ SEQUENCE 183 AA; 21050 MW; 0D5604AD29D529CF CRC64;
MERVQPLEEN VGNAARPRFE RNKLLLVASV IQGLGLLLCF TYICLHFSAL QVSHRYPRIQ
SIKVQFTEYK KEKGFILTSQ KEDEIMKVQN NSVIINCDGF YLISLKGYFS QEVNISLHYQ
KDEEPLFQLK KVRSVNSLMV ASLTYKDKVY LNVTTDNTSL DDFHVNGGEL ILIHQNPGEF
CVL
